Hematologic Malignancies Market Share To Reach USD 120.56 Billion By 2028, Trends – Increasing focus on development of new Therapeutics.
Rising
global prevalence of blood cancer, growing awareness about benefits of early
diagnosis, and development of strong pipeline therapeutics are key factors
driving market revenue growth
Market
Size – USD 53.46 Billion in 2020, Market Growth – at a CAGR of 10.7%, Market
Trends – Increasing focus on development of new therapeutics
The Global Hematologic
Malignancies Market size is expected to reach USD 120.56 Billion by
2028 at a CAGR of 10.7%, according to the latest report by Reports and Data.
Rising prevalence of blood cancer, presence of strong pipeline therapeutics,
and increasing expenditure in healthcare sector are key factors expected to
drive market revenue growth over the forecast period. In addition, rapidly
increasing geriatric population, rising awareness about early diagnosis and
treatment, growing focus on developing advanced therapeutics, and increasing
product approvals are expected to support market growth going ahead.
Hematologic
malignancies are cancers that affect bone narrow, blood, and lymph nodes, and
include different types of leukemia, myeloma, and lymphoma. Hematological
malignancies account for nearly 9% of total newly diagnosed cancers in the
United States. Blood cancer generally occur when there is rapid and
uncontrollable growth of abnormal cells which interfere with development and
functioning of normal cells. Hematologic malignancies are subdivided according
to the type of blood cells that are affected. Lymphoblastic or lymphocytic
malignancies occur in the lymphoid lineage, while myelogenous or myeloid
malignancies occur in myeloid lineages. Treatment of hematologic malignancies
is largely based on treating and alleviating symptoms. Aggressive hematologic
malignancies require treatment with chemotherapy, immunotherapy, radiotherapy,
and bone marrow transplant. increasing number of patients requiring
chemotherapy and bone marrow transplant has increased over the recent past and
this is expected to drive demand for these therapeutic approaches going ahead.
Get a
sample of the report @ https://www.reportsanddata.com/discount-enquiry-form/4056
Over the last
decade, numerous preclinical and clinical researches have generated encouraging
results for treatment of hematological malignancies. Improved long-term
outcomes for patients suffering from hematologic malignancies owing to rapid
progress in therapeutics and drugs has contributed significantly to revenue
growth of the market. Increasing funding and investment to accelerate cancer
research is also expected to drive market growth. However, high costs of
treatment and lack of skilled professionals is expected to restrain market
growth to a certain extent over the forecast period.
Some Key
Highlights From the Report:
- Leukemia segment is expected to register robust revenue
growth over the forecast period owing to increasing prevalence of leukemia
across the globe, availability of advanced oncology drugs and
therapeutics, and increasing collaborations in the market to boost
development of advanced therapeutics for leukemia.
- Chemotherapy segment is expected to account for largest
revenue share during the forecast period, attributable to increasing
application of chemotherapy in treatment of blood cancer. Chemotherapy is
generally the first line of treatment for blood cancer and often uses a
combination of drugs depending on the type of cancer.
- North America is expected to account for largest
revenue share between 2021 and 2028, attributable to rising prevalence of
hematologic malignancies, establishment of robust healthcare facilities,
availability of advanced cancer therapeutics, and robust presence of key
market players in the region.
- Key players include Pfizer, Inc., F. Hoffmann-LA Roche
ltd., Sanofi-Aventis, Bristol-Myers Squibb Company, AbbVie, Inc., Novartis
AG, GlaxoSmithKline PLC, Celgene Corporation, Johnson & Johnson
Services, Inc., and Takeda Pharmaceutical Company Limited.
- In April 2021, Arch Oncology, Inc., which is a
clinical-stage oncology firm engaged in discovery and development of
anti-CD47 therapeutics, closed a Series C round of financing at USD 105
Million. The funding will be used to accelerate clinical progress of
differentiated anti-CD47 candidate for treating patients with solid tumors
and hematologic malignancies.
Request a
discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/4056
For the purpose of
this report, Reports and Data has segmented the hematologic malignancies market
based on type, therapy, and region:
Type
Outlook (Revenue, USD Billion; 2018-2028)
- Leukemia
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Acute Myeloid Leukemia
- Chronic Myeloid Leukemia
- Lymphoma
- Multiple Myeloma
- Others
Therapy
Outlook (Revenue, USD Billion; 2018-2028)
- Chemotherapy
- Radiotherapy
- Immunotherapy
- Stem Cell Transplantation
- Others
Regional
Outlook (Revenue, USD Billion; 2018-2028)
- North America
- S.
- Canada
- Mexico
- Europe
- Germany
- K.
- Italy
- France
- BENELUX
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- A.E.
- South Africa
- Rest of MEA
To know
more about the report @ https://www.reportsanddata.com/report-detail/hematologic-malignancies-market
- Table of Contents
- Chapter 1. Global Hematologic Malignancies Market
Definition and Scope
- Chapter 2. Research Methodology
- Chapter 3. Executive Summary
- Chapter 4. Global Hematologic Malignancies Market
Dynamics
- Chapter 5. Global Hematologic Malignancies Market
Competitive Landscape
- Chapter 6. Global Hematologic Malignancies Market by
Product Types
- Chapter 7. Global Hematologic Malignancies Market by
Applications
- Chapter 8. Global Hematologic Malignancies Market by
End-user industries
- Chapter 9. Global Hematologic Malignancies Market
Regional Analysis
- Chapter 10. Appendix
The Hematologic
Malignancies Market Report discusses the changing economic scenario,
highlighting market value and volume, drivers, constraints, opportunities,
challenges, demand and supply ratio, production capacity, import/export status,
growth rate, and others. The report also utilizes analytical and econometric
tools to assess key information.
Request
customization of the report @ https://www.reportsanddata.com/request-customization-form/4056
Thank you
for reading our report. For further details or to inquire about customization,
please let us know and we will offer you the report as per your needs.
Table of
Content:
Chapter 1
Research Methodology & Scope
1.1 Information
Procurement
1.1.1 Purchased database:
1.1.2 Internal database
1.2 Research
Methodology
1.3 Geographic
scope & assumptions
1.4 Region-wise
market calculation
1.4.1 Region-wise market: Base estimates
1.4.2 Global market: CAGR calculation
1.5 Region-based
segment share calculation
1.6 List of
Secondary Sources
Chapter 2 Executive Summary
2.1 Market
Snapshot
Chapter 3 Hematologic
Malignancies Market Variables, Trends & Scope
3.1 Market
segmentation& scope
3.2 Market Driver
Analysis
3.2.1 Growing Incidence of blood cancer
3.2.2 Increasing investment for cancer research
3.2.3 Strong product pipeline
3.2.4 Increasing Acquisition and Collaboration
3.3 Market
restraint analysis
3.3.1 Reimbursement Policies
3.3.2 Large Capital Investment
3.4 Penetration
& growth prospect mapping
3.5 Hematologic
malignancies - SWOT Analysis, By Factor (political & legal, economic and
technological)
3.6 Industry
Analysis - Porter’s
Chapter 4 Hematologic
Malignancies Market: Type Outlook
Continued…..
Comments
Post a Comment